246 related articles for article (PubMed ID: 37676710)
21. MicroRNA Regulation of Androgen Receptor in Castration-Resistant Prostate Cancer: Premises, Promises, and Potentials.
Ebrahimi S; Hashemy SI; Sahebkar A; Aghaee Bakhtiari SH
Curr Mol Pharmacol; 2021 Oct; 14(4):559-569. PubMed ID: 33357209
[TBL] [Abstract][Full Text] [Related]
22. Androgen receptor targeted therapies in castration-resistant prostate cancer: Bench to clinic.
Imamura Y; Sadar MD
Int J Urol; 2016 Aug; 23(8):654-65. PubMed ID: 27302572
[TBL] [Abstract][Full Text] [Related]
23. Targeting prosurvival BCL2 signaling through Akt blockade sensitizes castration-resistant prostate cancer cells to enzalutamide.
Pilling AB; Hwang C
Prostate; 2019 Aug; 79(11):1347-1359. PubMed ID: 31228231
[TBL] [Abstract][Full Text] [Related]
24. Targeting androgen-independent pathways: new chances for patients with prostate cancer?
Cattrini C; Zanardi E; Vallome G; Cavo A; Cerbone L; Di Meglio A; Fabbroni C; Latocca MM; Rizzo F; Messina C; Rubagotti A; Barboro P; Boccardo F
Crit Rev Oncol Hematol; 2017 Oct; 118():42-53. PubMed ID: 28917268
[TBL] [Abstract][Full Text] [Related]
25. Androgen Receptor Variants Confer Castration Resistance in Prostate Cancer by Counteracting Antiandrogen-Induced Ferroptosis.
Sun R; Yan B; Li H; Ding D; Wang L; Pang J; Ye D; Huang H
Cancer Res; 2023 Oct; 83(19):3192-3204. PubMed ID: 37527336
[TBL] [Abstract][Full Text] [Related]
26. Sequencing strategies in the new treatment landscape of prostate cancer.
Caffo O; Maines F; Kinspergher S; Veccia A; Messina C
Future Oncol; 2019 Sep; 15(25):2967-2982. PubMed ID: 31424285
[TBL] [Abstract][Full Text] [Related]
27. A novel AR translational regulator lncRNA LBCS inhibits castration resistance of prostate cancer.
Gu P; Chen X; Xie R; Xie W; Huang L; Dong W; Han J; Liu X; Shen J; Huang J; Lin T
Mol Cancer; 2019 Jun; 18(1):109. PubMed ID: 31221168
[TBL] [Abstract][Full Text] [Related]
28. Targeting Oct1 genomic function inhibits androgen receptor signaling and castration-resistant prostate cancer growth.
Obinata D; Takayama K; Fujiwara K; Suzuki T; Tsutsumi S; Fukuda N; Nagase H; Fujimura T; Urano T; Homma Y; Aburatani H; Takahashi S; Inoue S
Oncogene; 2016 Dec; 35(49):6350-6358. PubMed ID: 27270436
[TBL] [Abstract][Full Text] [Related]
29. A COP1-GATA2 axis suppresses AR signaling and prostate cancer.
Shen T; Dong B; Meng Y; Moore DD; Yang F
Proc Natl Acad Sci U S A; 2022 Oct; 119(43):e2205350119. PubMed ID: 36251994
[TBL] [Abstract][Full Text] [Related]
30. Androgen receptor negatively regulates mitotic checkpoint signaling to induce docetaxel resistance in castration-resistant prostate cancer.
Pilling A; Kim SH; Hwang C
Prostate; 2022 Feb; 82(2):182-192. PubMed ID: 34672379
[TBL] [Abstract][Full Text] [Related]
31. Exploring anti-androgen therapies in hormone dependent prostate cancer and new therapeutic routes for castration resistant prostate cancer.
Harris AE; Metzler VM; Lothion-Roy J; Varun D; Woodcock CL; Haigh DB; Endeley C; Haque M; Toss MS; Alsaleem M; Persson JL; Gudas LJ; Rakha E; Robinson BD; Khani F; Martin LM; Moyer JE; Brownlie J; Madhusudan S; Allegrucci C; James VH; Rutland CS; Fray RG; Ntekim A; de Brot S; Mongan NP; Jeyapalan JN
Front Endocrinol (Lausanne); 2022; 13():1006101. PubMed ID: 36263323
[TBL] [Abstract][Full Text] [Related]
32. TCF7 is suppressed by the androgen receptor via microRNA-1-mediated downregulation and is involved in the development of resistance to androgen deprivation in prostate cancer.
Siu MK; Chen WY; Tsai HY; Chen HY; Yin JJ; Chen CL; Tsai YC; Liu YN
Prostate Cancer Prostatic Dis; 2017 Jun; 20(2):172-178. PubMed ID: 28220803
[TBL] [Abstract][Full Text] [Related]
33. Angiogenin mediates androgen-stimulated prostate cancer growth and enables castration resistance.
Li S; Hu MG; Sun Y; Yoshioka N; Ibaragi S; Sheng J; Sun G; Kishimoto K; Hu GF
Mol Cancer Res; 2013 Oct; 11(10):1203-14. PubMed ID: 23851444
[TBL] [Abstract][Full Text] [Related]
34. A genome-scale CRISPR screen reveals PRMT1 as a critical regulator of androgen receptor signaling in prostate cancer.
Tang S; Sethunath V; Metaferia NY; Nogueira MF; Gallant DS; Garner ER; Lairson LA; Penney CM; Li J; Gelbard MK; Alaiwi SA; Seo JH; Hwang JH; Strathdee CA; Baca SC; AbuHammad S; Zhang X; Doench JG; Hahn WC; Takeda DY; Freedman ML; Choi PS; Viswanathan SR
Cell Rep; 2022 Feb; 38(8):110417. PubMed ID: 35196489
[TBL] [Abstract][Full Text] [Related]
35. Gremlin1 is a therapeutically targetable FGFR1 ligand that regulates lineage plasticity and castration resistance in prostate cancer.
Cheng C; Wang J; Xu P; Zhang K; Xin Z; Zhao H; Ji Z; Zhang M; Wang D; He Y; Jing N; Fan L; Liu K; Li F; Liu C; Gong Y; Cui S; Sun Z; Sun D; Yao X; Li H; Zhang J; Zhang P; Dong B; Xue W; Qian X; Gao WQ; Zhu HH
Nat Cancer; 2022 May; 3(5):565-580. PubMed ID: 35624341
[TBL] [Abstract][Full Text] [Related]
36. LINC00675 activates androgen receptor axis signaling pathway to promote castration-resistant prostate cancer progression.
Yao M; Shi X; Li Y; Xiao Y; Butler W; Huang Y; Du L; Wu T; Bian X; Shi G; Ye D; Fu G; Wang J; Ren S
Cell Death Dis; 2020 Aug; 11(8):638. PubMed ID: 32801300
[TBL] [Abstract][Full Text] [Related]
37. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
Shafi AA; Yen AE; Weigel NL
Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
[TBL] [Abstract][Full Text] [Related]
38. Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer.
Liu C; Lou W; Zhu Y; Nadiminty N; Schwartz CT; Evans CP; Gao AC
Clin Cancer Res; 2014 Jun; 20(12):3198-3210. PubMed ID: 24740322
[TBL] [Abstract][Full Text] [Related]
39. Lineage plasticity-mediated therapy resistance in prostate cancer.
Blee AM; Huang H
Asian J Androl; 2019; 21(3):241-248. PubMed ID: 29900883
[TBL] [Abstract][Full Text] [Related]
40. A hormone-dependent feedback-loop controls androgen receptor levels by limiting MID1, a novel translation enhancer and promoter of oncogenic signaling.
Köhler A; Demir U; Kickstein E; Krauss S; Aigner J; Aranda-Orgillés B; Karagiannidis AI; Achmüller C; Bu H; Wunderlich A; Schweiger MR; Schaefer G; Schweiger S; Klocker H; Schneider R
Mol Cancer; 2014 Jun; 13():146. PubMed ID: 24913494
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]